ASXL1 is altered in 50.0% of chronic myelomonocytic leukemia-2 patients [2].

ASXL1 is an inclusion eligibility criterion in 1 clinical trial for chronic myelomonocytic leukemia-2, of which 1 is open and 0 are closed. Of the trial that contains ASXL1 status and chronic myelomonocytic leukemia-2 as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MECOM is an inclusion eligibility criterion in 1 clinical trial for chronic myelomonocytic leukemia-2, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and chronic myelomonocytic leukemia-2 as inclusion criteria, 1 is phase 3 (1 open) [3].

MLF1 is an inclusion eligibility criterion in 1 clinical trial for chronic myelomonocytic leukemia-2, of which 1 is open and 0 are closed. Of the trial that contains MLF1 status and chronic myelomonocytic leukemia-2 as inclusion criteria, 1 is phase 3 (1 open) [3].

NPM1 is altered in 7.14% of chronic myelomonocytic leukemia-2 patients [2].

NPM1 is an inclusion eligibility criterion in 1 clinical trial for chronic myelomonocytic leukemia-2, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and chronic myelomonocytic leukemia-2 as inclusion criteria, 1 is phase 3 (1 open) [3].

NRAS is altered in 57.14% of chronic myelomonocytic leukemia-2 patients [2].

NRAS is an inclusion eligibility criterion in 1 clinical trial for chronic myelomonocytic leukemia-2, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and chronic myelomonocytic leukemia-2 as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RPN1 is an inclusion eligibility criterion in 1 clinical trial for chronic myelomonocytic leukemia-2, of which 1 is open and 0 are closed. Of the trial that contains RPN1 status and chronic myelomonocytic leukemia-2 as inclusion criteria, 1 is phase 3 (1 open) [3].

RUNX1 is altered in 35.71% of chronic myelomonocytic leukemia-2 patients [2].

RUNX1 is an inclusion eligibility criterion in 1 clinical trial for chronic myelomonocytic leukemia-2, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 status and chronic myelomonocytic leukemia-2 as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SETBP1 is an inclusion eligibility criterion in 1 clinical trial for chronic myelomonocytic leukemia-2, of which 1 is open and 0 are closed. Of the trial that contains SETBP1 status and chronic myelomonocytic leukemia-2 as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TP53 is altered in 7.14% of chronic myelomonocytic leukemia-2 patients [2].

TP53 is an inclusion eligibility criterion in 1 clinical trial for chronic myelomonocytic leukemia-2, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and chronic myelomonocytic leukemia-2 as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].